Job Seekers, Welcome to AEA Career Center
Use this area to filter your search results. Each filter option allows for multiple selections.
Search Results: 374 Jobs
Loading... Please wait.
City of Edmonton
Edmonton, Alberta, Canada
City of Oregon City Public Works Department
Oregon City, Oregon
University of California Santa Cruz
Santa Cruz, California
City of Hope
Loading... Please wait.
About NIH National Human Genome Research Institute & FDA Office of Minority Health and Health Equity
The National Human Genome Research Institute (NHGRI) was established originally as the National Center for Human Genome Research in 1989 to lead the International Human Genome Project. NHGRI is part of the National Institutes of Health (NIH), the nation’s medical research agency. NHGRI funds and conducts research to uncover the role that the genome plays in human health and disease. This research occurs across a spectrum: basic research to shed light on the structure and function of the genome; translational research to decipher the molecular bases of human diseases; and clinical research to establish how to use genomic information to advance medical care. NHGRI also supports exploration of the complex ethical, legal, and social implications of genomics, and is committed to ensuring that the knowledge and benefits generated from genomics research are disseminated widely, both to fuel current and future researchers and to benefit the general public and promote genomic literacy. The Food and Drug Administration (FDA) is responsible for advancing the public health by helping to speed innovations that make medical products more effective, safer, and more affordable and by helping ...the public get the accurate, science-based information they need to use medical products and foods to maintain and improve their health. The FDA Office of Minority Health and Health Equity (OMHHE) serves to promote and protect the health of diverse populations through research and communication of science that addresses health disparities. The FDA OMHHE aims to: (1) increase the amount of clinical trial data available on racial and ethnic minorities; improve the data quality to determine how minorities react to medical products; and increase transparency and access to available data; (2) strengthen FDA’s ability to respond to minority health concerns and (3) promote health and safety communication to minority populations who often experience low health literacy and/or speak English as a second language.
Loading. Please wait.